ABT News 42.24 09/02/2014 04:22:23 Abbott Laboratories (ABT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbott Laboratories (ABT) 42.24 $ABT

Fitch Maintains CFR's IDRs on Rating Watch Positive
Business Wire - Fri Aug 29, 12:47PM CDT
Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release.

Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART D: ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery

Global Infant Formula Market Report: Focus on China 2014
M2 - Thu Aug 28, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twqn7f/global_infant) has announced the addition of the "Global Infant Formula Market Report: Focus on China" report to their offering. The market for infant formula products is one of the major and the fastest growing segments of the overall baby foods industry. Infant formula is either a partial or a total substitute for breast milk for infants and is recommended for feeding during the first twelve months. Since the start of the millennium, international awareness regarding the importance of early childhood nutrition has been on the rise. All over the world parents are becoming more concerned about the nutritional benefit of pediatric foods and breast-milk supplements. Increasing proportion of women participation in labor force and increased affordability supported by waning price responsiveness and a rise in disposable income across the world are the major factors that have helped the global IMF market to attain stronger growth levels. Though the market has been experiencing lower demand and growth from the traditional matured markets of the West stemming primarily from declining birth rate, the developing world, especially the Asia and Pacific region and Latin America have provided the headroom for the global market expansion. The market is dominated by the Asian region which consumes about three-fifths of the global IMF supplies. Particularly, China has gained the stature to maneuver the market single-handedly since the country alone accounts for about two-fifth of the global IMF market revenues. The report, Global Infant Formula Market prudently analyzes the development of the respective market, with a focus on the single largest market, China, and other regional but important markets. The report discusses the major trends, growth drivers as well as issues being faced by the industry. The global infant formula market is predominated by a handful of players including Nestl?, Danone, Mead Johnson Nutrition and Abbott which keep vying for greater market share. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. . Key Topics Covered: 1. Market Overview 2. Baby Food/Infant Nutrition Market 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abbott Laboratories - Danone S.A. - Mead Johnson Nutrition Co. - Nestl? S.A. For more information visit http://www.researchandmarkets.com/research/tw...bal_infant

Frustrating Boston Scientific Is Not What the Investor Ordered
at The Street - Thu Aug 28, 5:30AM CDT
It will only take one bad quarter for shares to fall to single digits. That's the only time you should buy.

Abbott Laboratories Has Returned 10.4% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Wed Aug 27, 10:05AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 4 months, Abbott Laboratories has returned 10.39% as of today's recent price of $42.77.

Home Healthcare Global Market Report - Forecast to 2020 for the $300 Million Industry
M2 - Wed Aug 27, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbsmjs/home_healthcare) has announced the addition of the "Home Healthcare Global Market - Forecast to 2020" report to their offering. Global home healthcare market is expected to reach more than $300 billion by 2019 growing at a CAGR of around 8.0% from 2014 to 2019 The home healthcare equipment market is expected to grow at a faster rate compared to home healthcare services market. Home healthcare is gaining a tremendous attention over hospitals for the sophistication, ease and privacy of treatment it offers. Increased in-hospital care cost, comfort of recovering at home and enhanced age-related chronic diseases in developing as well as developed countries are factors driving the overall growth of home healthcare market. Whereas factors such as poor technology adoption, weak reimbursement policies and rapidly changing technologies are hampering the market growth. Moreover, high capital costs, medical equipment, human resources and conventional model of business are the challenges faced by home healthcare market. The opportunities increasing the market trend is attributed to medical insurance by governments or organizations and cost-effectiveness.North America adopting novel technologies and portable diagnostic devices accounts for the largest share in the home healthcare market. While Europe with the presence of well-equipped healthcare reimbursement structure is the second leading market. Asia-Pacific is expected to grow at the highest CAGR driven by the aging population in countries such as India, China, and Japan. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Home Healthcare Therapeutic Equipment Market 5. Home Healthcare Services Market 6. Home Healthcare Telehealth Market 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - Abbott Laboratories - Baxter International - Braun - Novo Nordisk - GE Healthcare - Invacare - Johnson and Johnson - Medtronic - Philips Healthcare - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/lb...healthcare

Microfluidic Device System Market 2013 - 2019
M2 - Wed Aug 27, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x345bg/microfluidic) has announced the addition of the "Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global microfluidic device market was valued at USD 1,531.2 million in 2013. It is likely to grow at a CAGR of 22.8% during 2013 to 2019 to reach USD 5,246.4 million in 2019. Microfluidics is an evolving scientific field with numerous analytical applications and commercial potential. Globally, the microfluidic device market is witnessing significant growth due to increasing R&D investment in pharmaceuticals, life science and rising point of care testing demand. New trends in healthcare, such as healthcare at home, supports point of care testing (POCT) as the most efficient and effective delivery of healthcare. It has many applications in other areas such as drug screening, sugar testers, chemical micro reactor, microprocessor cooling and micro fuel cells. Rising demand for point of care testing, miniaturization of chip, and increasing demand for microfluidic devices in genomics and proteomics are the key growth drivers for the microfluidic device market. In addition, change in material mix would provide opportunity for new market entrants, which would further drive the growth of the microfluidic device market. North America was valued at USD 644.5 million in 2013 and is expected to reach USD 2,095.5 million in 2019, growing at a CAGR of 21.7% from 2013 to 2019. In-vitro diagnostics microfluidic device market was valued at USD 949.6 million in 2013 and is expected to reach USD 3,317.4 million in 2019, growing at a CAGR of 23.2% from 2013 to 2019. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Industry Analysis Chapter 4 Market Trends Chapter 5 Porters Five Force Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis - by Material Chapter 8 Segment Analysis - by Industry Chapter 9 Segment Analysis - by Application Chapter 10 Regional Analysis Chapter 11 Competitive Landscape Chapter 12 Company Profiles - Abbott Laboratories - Agilent Technologies Inc - Becton, Dickinson and Company - Bio- Rad Laboratories - Cepheid - Dolomite Centre - Fluidigm Corporation - Johnson & Johnson - Micronit Microfluidics - RainDance Technologies - Roche Diagnostics - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/x3...crofluidic

Abbott Laboratories (ABT) Breaks Through Resistance at $42.70
Comtex SmarTrend(R) - Tue Aug 26, 10:41AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $42.49 today and have reached the first resistance level of $42.70. Should the shares continue to rise, the resistance pivots of $42.92 and $43.35 will be of interest.

Collaborations, New Contract, Dividend Declaration, and Capacity Expansion - Research Reports on Abbott, CB&I, Weyerhaeuser, Cardinal Health and SolarCity
PR Newswire - Tue Aug 26, 7:50AM CDT
Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Chicago Bridge & Iron Company N.V. (NYSE: CBI), Weyerhaeuser Co. (NYSE: WY), Cardinal Health, Inc. (NYSE: CAH) and SolarCity Corporation (NASDAQ: SCTY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5978-100free.

North American Interventional Cardiology & Peripheral Vascular Devices (Angioplasty Balloon, Stent, Catheter, IVC Filter, Endovascular Stent Graft) Market Report
M2 - Tue Aug 26, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxpdkk/north_american) has announced the addition of the "North American Interventional Cardiology & Peripheral Vascular Devices Market by Angioplasty Balloon, Stent, Catheter, IVC Filter, Endovascular Stent Graft - Forecast to 2018" report to their offering. The North American interventional cardiology and peripheral vascular devices market is expected to grow at a CAGR of 2.9% from 2013 to 2018. Both, the lower volume of coronary angioplasty procedures and the increasing prevalence rate of peripheral artery diseases have impacted the market significantly. Amongst all the product segments, bioabsorbable stents, retrievable inferior vena cava filters, and diagnostic catheters (intravascular ultrasound and optical coherence tomography catheters) markets are identified as the high growth segments in the North American interventional cardiology and peripheral vascular devices market. Better diagnosis of thrombus using IVUS and OCT catheters is expected to drive the diagnostic catheters market; whereas, lesser risk of long-term post surgical complications in DVT/PE treatments will encourage faster adoption of the retrievable inferior vena cava filters in the coming years. The bioabsorbable stents are still not available for clinical usage in the U.S. However, bioabsorbable stents are available on a special access basis by Health Canada. The usage factors of different surgical instruments were the major hindrances while deriving the market size of the corresponding surgical devices. This is primarily due to the availability of various surgical instruments for the treatment of similar cardiac ailments. For instance, coronary angioplasty can be performed through plain balloon catheter, stent, and/or a combination of stent and catheter, based on patients' cardiac health. The study on the North American interventional cardiology and peripheral vascular devices market captures an exhaustive list of surgical devices which are used in various types of angioplasty procedures, deep vein thrombosis, endovascular aneurysm repairing, and chronic total occlusion (CTO) treatment procedures. This research illustrates specific driving and restraining factors in the U.S. and Canadian markets; furthermore, it identifies the high-growth regions with regard to the interventional cardiology and peripheral vascular devices market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Angioplasty Balloons 6 Angioplasty Stents 7 Catheters Market 8 Endovascular Aneurysm Repair (EVAR) Stent Grafts Market 9 Inferior Vena Cava (IVC) Filters Market 10 Plaque Modification Devices Market 11 Hemodynamic Flow Alteration Devices Market 12 Accessory Devices Market 13 Geographic Analysis 14 Competitive Landscape 15 Company Profiles - Abbott Laboratories - Biotronik SE & Co. Kg - Boston Scientific Corporation - B. Braun Melsungen AG - Cook Medical, Inc. - Cordis Corporation - Covidien Plc - C. R. Bard, Inc. - Medtronic Inc. - W.L.Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/px...h_american

Nitinol Medical Devices Market Forecasts & Opportunities, 2019 - Semi-finished Raw Material & Final Medical Components Analysis
M2 - Tue Aug 26, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8xqrs/nitinol_medical) has announced the addition of the "Nitinol Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The total market of nitinol medical devices for final medical components was valued at USD 8,287.2 million in 2012 and is forecasted to grow at a CAGR of 11.1% during the period of 2013 to 2019. Based on the type of final medical components, the total market is subdivided into nitinol stents, guidewires and others, which comprises dental wires, catheter tubes, tissue ablators, needles, retrieval baskets, biopsy forceps, endodontic files and filters. Among these afore-mentioned components, nitinol stents market accounted for the largest market share in 2012 and is expected to retain its market share till 2019 due to increasing number of vascular stenting procedures globally. Additionally, growing medical device manufacturer's preference for using nitinol as a chief raw material owing to its unique biomechanical properties is further expected to drive the market for nitinol stents in coming years. Based on the type of semi-finished raw materials, the market is categorized into nitinol tubes, wiring and others, which comprise sheets and ribbons. The total market for nitinol semi-finished raw materials was valued at USD 1,525.2 million in 2012. Of these, the Nitinol-wiring market accounted for the largest market share in 2012. The contributing factors for such an assessment included a large number of clinical applications, low cost and better corrosion resistance properties compared to tubes and others. Nitinol wires are currently being deployed in various applications such as orthopedics, endoscopy, laparoscopy, catheter wall supports, ablation catheter, custom springs, etc. Geographically, North America constituted the largest market for global nitinol medical devices market in 2012; however, Asia-Pacific is predicted to foresee the fastest growth rate during the forecast period from 2013 to 2019. This high growth has been attributed to presence of large population base which consequently gives rise to large patient population, low treatment cost and increasing healthcare awareness among the patients. In addition, favorable government support and growing medical tourism industry would trigger the growth of this market in Asia-Pacific. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Nitinol Medical Devices Market, by Semi-finished Raw Material Chapter 5 Global Nitinol Medical Devices Market, by Final Medical Components Chapter 6 Global Nitinol Medical Devices Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - Boston Scientific Corporation - Cook Medical, Inc. - Covidien plc - C. R. Bard, Inc. - Custom Wire Technologies, Inc. - ENDOSMART GmbH - Medtronic, Inc. - Nitinol Devices & Components, Inc. - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/w8...ol_medical

MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook

MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas

MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews

Abbott Commences Tender Offer for All Outstanding Ordinary Shares and American Depositary Shares of CFR Pharmaceuticals S.A.
PR Newswire Europe - Mon Aug 25, 8:01AM CDT
Abbott today announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH" , has commenced a tender offer (the "U.S. Offer" , in which it is offering to purchase (i) from U.S. holders only, up to 100 percent of the outstanding ordinary, nominative, no par value shares (the "Ordinary Shares" of CFR Pharmaceuticals S.A. ("CFR" , a Chilean corporation and (ii) from all holders, wherever resident, up to 100 percent of the outstanding American Depositary Shares ("ADSs" issued pursuant to the Rule 144A Deposit Agreement or the Regulation S Deposit Agreement, each dated as of May 9, 2011, between CFR and The Bank of New York Mellon, as Depositary (the "ADS Depositary" , each of which represents 100 Ordinary Shares, in each case, on the terms and subject to the conditions set forth in the U.S. Offer to Purchase, dated Aug. 25, 2014, and in the related Ordinary Share Acceptance Letter and ADS Letter of Transmittal, as applicable.

Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
at The Street - Fri Aug 22, 3:55PM CDT
Emerging market pharmaceutical sales are exploding. Find out if Abbott Laboratories or Johnson & Johnson is best positioned to take advantage of the booming emerging market pharmaceutical market.

Health Care Equipment Equities Ahead of Market -- Medtronic, Abbott Laboratories, Zimmer Holdings, Stryker, and EnteroMedics
PR Newswire - Thu Aug 21, 7:50AM CDT
On Wednesday, August 20, 2014, the NASDAQ Composite ended at 4,526.48, down 0.02%, the Dow Jones Industrial Average advanced 0.35%, to finish the day at 16,979.13, and the S&P 500 closed at 1,986.51, up 0.25%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.51, up 0.01%, with the index also advancing 8.10% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Zimmer Holdings Inc. (NYSE: ZMH), Stryker Corporation (NYSE: SYK), and EnteroMedics Inc. (NASDAQ: ETRM). Free research on these five companies can be accessed at:

Global Biomarkers Markets Report 2014-2018: Cancer, Cardiac, Blood, Endocrine & Infectious Disease and Neurological Disease Markers
M2 - Thu Aug 21, 2:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dwnkk/the_global_market) has announced the addition of the "The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)" report to their offering. The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers. All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers' level. The base year for data was 2013. Historical data was provided for the years 2008 through 2012, with forecast data provided for 2014 through 2018. Compound annual growth rates (CAGRs) are provided for the 2008-2013 and 2013-2018 periods for each segment covered. Basic competitor summaries are included in each segment. The forecasted market analysis for 2014-2018 was largely based on demographic trends, new developments, biomarker development, company performance trends, merger and acquisitions, and global expansion. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems, Inc. - Abbott Laboratories - Affymetrix - Agendia, Inc. USA - Alere, Inc - Asuragen, Inc. - Beckman Coulter, Inc - Becton, Dickinson - BioReference Laboratories, Inc - Biocartis S.A. - Biodesix, Inc. - CARDIODX, INC - CELERA ALAMEDA - Clarient, Inc - DiaGenic ASA - Genomic Health, Inc. - Genoptix Medical Laboratory - Illumina, Inc. - Johnson & Johnson - Life Technologies Corporation - Memory Dx - Myriad Genetics, Inc. - Nanostring Technologies, Inc. - OPKO Health, Inc. - Qiagen N.V. - SIEMENS HEALTHCARE - Thermo Fisher Scientific - bioMerieux SA - biotheranostics, Inc. - deCODE Genetics, Inc. For more information visit http://www.researchandmarkets.com/research/5d...bal_market
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 78

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 89

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 41

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 26

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 119

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 45

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 147

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 55

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 35

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 85

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover AM Best's New Bookstore for Insurance Insights

Updated Category News Views 92

AM Best Unveils Innovative Bookstore for Insurance Readers AM Best recently launched the AM Best’s Bookstore, a unique digital platform designed for those interested in deeper insights into the insurance sector. This bookstore serves as a central hub for information on newly published books that cover a wide range of topics pertinent to the insurance industry....

Continue Reading
Aurora Mobile Hits a Milestone with Strong Q2 Financials

Updated Category News Views 174

Aurora Mobile Reports Impressive Second Quarter Financial Results Aurora Mobile Limited, recognized for its customer engagement and marketing technology services, has revealed its financial metrics for the second quarter of 2025. This quarter has marked a groundbreaking achievement with the company recording its inaugural quarterly net income under U.S. GAAP. Financial...

Continue Reading
Meta Platforms' Competitive Edge in Media and Services Sector

Updated Category News Views 279

Understanding Meta Platforms in its Industry Context In the fast-paced realm of Interactive Media & Services, comprehensive analysis is vital for both investors and market analysts. This article dives into an industry comparison, focusing on Meta Platforms (NASDAQ: META) along with its prominent competitors. By evaluating crucial financial indicators, market standings,...

Continue Reading
Investigation by Rosen Law Firm for Kaspi.kz Investors

Updated Category News Views 88

Rosen Law Firm's Investigation of Kaspi.kz Security Claims The Rosen Law Firm, globally recognized for protecting investor rights, has launched an investigation regarding potential securities claims for shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI). This investigation stems from serious allegations that Kaspi.kz may have disseminated misleading business...

Continue Reading
Praxis Precision Medicines to Showcase Innovations This Fall

Updated Category News Views 158

Upcoming Investor Conferences for Praxis Precision Medicines Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a dynamic entity in the field of biopharmaceuticals, has an exciting roster of events lined up this fall. The company is dedicated to developing therapies aimed at addressing central nervous system (CNS) disorders that are driven by imbalances in neuronal...

Continue Reading